This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge repair, mitral valve surgery or medical/conservative therapy.
Mitral Regurgitation
This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge repair, mitral valve surgery or medical/conservative therapy.
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
-
Cedars-Sinai Medical Center, Los Angeles, Los Angeles, California, United States, 90048
Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115
Houston Methodist Hospital, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Universitätsklinikum Hamburg-Eppendorf,
Lenard Conradi, MD, PRINCIPAL_INVESTIGATOR, University Heart and Vascular Center Hamburg
Thomas Modine, MD, PRINCIPAL_INVESTIGATOR, University Hospital, Bordeaux
Sebastian Ludwig, MD, PRINCIPAL_INVESTIGATOR, University Heart and Vascular Center Hamburg
Walid Ben Ali, MD, PRINCIPAL_INVESTIGATOR, Montreal Heart Institute
Alison Duncan, MD, PRINCIPAL_INVESTIGATOR, Royal Brompton Hospital London
Gilbert Tang, MD, PRINCIPAL_INVESTIGATOR, Mount Sinai Medical Center, NYC
Juan F Granada, MD, PRINCIPAL_INVESTIGATOR, Cardiovascular Research Foundation, New York, USA
2030-12-31